Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Nivolumab 360mg|DRUG: Paclitaxel 80mg/m^2|DRUG: Doxorubicin 60mg/m^2|DRUG: Cyclophosphamide 600mg/m^2|DRUG: Paclitaxel 80mg/m^2 or Docetaxel 75mg/m^2|DRUG: Trastuzumab 8mg/kg and 6 mg/kg|DRUG: Pertuzumab 840mg and 420mg
Sponsor: NYU Langone Health